New generation transgenic techniques in rabbits



László Hiripi National Agricultural Research and Innovation Center, Gödöllő

2nd Congress of the Slovenian Society for Laboratory Animals

Why to use rabbits as model animals

• Prenatal development (especially long lasting effects on health and complex disorders)



•Diabetic pregnancy



•Atherosclerosis (Spontan mutants), transgenic rabbits






•Eye research (retinal degeneration)



•Arrhythmogenesis/ heart diseases



•Antibody production



Transgenic rabbit as a bioreactor

Ruconest- Human C1 inhibitor



Produced in the milk of transgenic rabbits

For the treatment of hereditary angioedema





Alpha glucosidase produced in the milk of TR. Rabbits-For Pompe disease Clinical trials phase III





First generation transgenic method was microinjection in rabbits






Surgical transfer





Problems and solutions

Transgenic rabbits



Additive transgenesis

Problem: efficiency

Targeted transgenesis (knock-out, knock in, allele exchange)

Problem: ES cells



New technologies: Transposon transgenesis

nuclease technologies

Transposon mediated transgenesis



RNA TRANSPOSON




DNA TRANSPOSON




Important in biotecnology

Transzposons are effective weapons in different fields of biotechnology



Insertional mutagenesis

How it works



The Sleeping Beauty system

•DNA transposon (Tc1/mariner)

•Reconstructed from salmon

•100X more efficient type by mutagenesis


•Integration to TA sequence

•Works in different species





Elements of SB-100 System

1.



2.






RESULTS


| Embryos | Transferred | No. mothers | Efficiency | TG lines |
|---------|-------------|---------------|--------------|----------|
| 644 | 472 | 25/10 40 % | 7/46 15 % | 4 |






Determination of integration sites, copy number

| Founders | Integration | |
|--------------------|-------------|--|
| | site | |
| SB ₃ JT | 19 Chr | |
| SB ₃ BT | 8 Chr | |



Expression




Liver Testis


Summary

| | Microinjection | Transposon | |
|------------------------|----------------|-----------------------------------|--|
| Efficiency | 1-6 % | 15% | |
| Capacity | >2 Mb | <6 kb | |
| Integration | randomly | Randomly (TA) | |
| Form of integration | Concatamers | Single copy 1-3 integration sites | |
| Expression | ++++ | +++++ | |
| Transgene transmission | ++++ | ++++ | |


How to use our GFP rabbit

-Produce rabbit pluripotent stem cell lines






-experimental surgery methods (cornea, cartilage)



"Designer nuclease technology"





- Artificial systems based on natural protein systems
- •Always harbour DNA binding part and a cleavage domain


Work as specific molecular scissors


Zinc finger nuclease Talen nuclease RNA mediated Crispr system

ZFN in rabbits- IGM targeted










Our experiences with Zinc finger nuclease in rabbits

- •Very effective: 20-25% of founders are positive
- •Founders are usually mosaic (less than 50% of F1 generation are mutant)
- •Founders always transmit transgene to F1
- •F1 generation can carry a different mutation than founder's ear. Special mosaicism.

 $\Delta 2$ mutation vs $\Delta 4+1$

Why we have mosaic founders?




TALEN experiments in rabbits

One published paper with 2 different knock outs

TALEN rabbit experiments in our lab


| Flushed zygotes | Transferred zygotes | Recipients/ deliveries | Transgenics/new borns |
|-----------------|---------------------|---------------------------|--------------------------|
| 213 | 178 | 10/5 50% | ?/15 |

CRISP-R was extremly efficient in rabbits



| Target gene | No. of embryos injected | No. of BL (%) | No. of BL sequenced | Mutants (%) | Bi-allelic mutations (%) |
|----------------|-------------------------|------------------|---------------------|-------------|-----------------------------|
| CD36 | 25 | 15 (60.0) | 15 | 10 (66.7) | 8 (80.0) |
| LDLR | 18 | 11 (61.1) | 10 | 5(50.0) | 0 (0) |
| CFTR | 60 | 33 (55.0) | 19 | 11 (55.6) | 4 (36.3) |
| APOE | 67 | 33 (49.2) | 23 | 16 (69.6) | 16 (100) |
| APOCIII | 38 | 13 (34.2) | 9 | 4 (44.4) | 0 (0) |
| LEP | 18 | 12 (66.7) | 12 | 2(16.7) | 0 (0) |
| LEPR | 19 | 13 (68.4) | 10 | 1(10.0) | 0 (0) |
| RyR2 | 20 | 13 (65) | 10 | 10 (100.0) | 8 (80.0) |
| SCARB1 | 25 | 16 (64.0) | 8 | 2 (25.0) | 0 (0) |
| Total | 290 | 159 (54.8) | 116 | 61 (52.6) | 36 (59.0) |

Targeted insertion is possible but not reported in rabbits



The result is homologous recombination and gene knock in or allele exchange

Nuclease technology is the ultimate technique to produce targeted gene modifications

- •Relatively cheap
 - Very specific
- •Efficient in rabbits
- Any targeting event can be produced
- •Even single bp exchange can be tested
 - •TRACELESS TECHNOLOGY
- •Open a new era for large animal models

REGULATION???

Thank you for attention!



